Janssen Pharmaceutica Nv

Janssen Research & Development, LLC

Margery Connelly

Mark J Macielag

Michael Nicholas Greco

Christopher M Flores

Hong Ye

Dennis J Hlasta

Edward Charles Lawson

Shyamali Ghosh

Eric D Strobel

Tom Parry

Michele Ann Weidner-Wells

Bruce P Damiano

Wensheng Lang

Edward C Giardino

Jian-Shen Qi

Disclosed are compounds, compositions and methods for treating metabolic diseases, including obesity and diabetes. Such compounds are represented by formula (I) as follows: wherein Y and Z are defined herein.

Monoacylglycerol lipase inhibitors for the treatment of metabolic diseases and related disorders

The present invention is directed to tricyclic indole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by endothelial lipase, for example, cardiovascular disorders.

Tricyclic indole derivatives useful endothelial lipase inhibitors

A method for identifying a compound which modulates the activity of acyl-coA: diacylglycerol acyltransferase comprises the steps of contacting a stable isotope labeled fatty acid with cells in either presence or absence of the compound, extracting the cells with isopropyl alcohol, and determining the level of a stable isotope labeled triglyceride in the presence or absence of the compound; wherein a change in the level of the stable isotope labeled triglyceride indicates that the compound modulates the DGAT activity.

Cell based screening assays for the triglyceride synthesis pathway

Disclosed are compounds, compositions and methods for treating metabolic diseases, including obesity and diabetes, and for reducing weight gain. Such compounds are represented by formula (I) as follows: wherein Y and Z are defined herein.

A method for evaluating the effect of a compound on vasomotor response in vivo comprises the steps of administering said compound to a rabbit and measuring the diameter of the vessel lumen of a central ear artery of said rabbit in comparison with the baseline diameter of the vessel lumen of said central ear artery of said rabbit, said baseline diameter being measured prior to the administration of said compound.

Animal model for evaluating vasomotor response in vivo

The present invention is directed to &#x3b1;-ketoamide derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by endothelial lipase, for example, cardiovascular disorders.

Growing community of inventors

Lansdale, PA, United States of America

Margery Connelly